New hope for rare lymphoma: duvelisib faces off against standard chemo
Disease control
Recruiting now
This phase 3 trial tests the drug duvelisib against two standard chemotherapy drugs (gemcitabine or bendamustine) in 124 people with a rare type of lymphoma (nodal T cell lymphoma with TFH phenotype) that has returned or not responded to prior treatment. The main goal is to see i…
Phase: PHASE3 • Sponsor: SecuraBio • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC